The 2026 DHHS Unified Agenda, released July 3, contains five regulatory shifts that together amount to the most concentrated set of proposed changes to clinical research rules in years, and research operations teams have a narrow window to decide which ones warrant preparation now versus a wait-and-see stance. The honest answer from the agenda itself: inclusion in this document does not make any of these actions effective, and several may never reach final form. That distinction matters because misreading a planned action as an active requirement is itself a compliance risk.
Two items deserve the most immediate attention. FDA’s expedited Phase 1 IND reform (RIN 0910-AJ30, NPRM targeted July 2026) could revise sponsor responsibilities, risk-based exemptions, and IRB requirements in early development, with the explicit goal of reducing what FDA characterizes as disproportionate burden. The agency flags its own concern: faster access creates real risk if sponsors interpret new flexibilities inconsistently, raising safety and data quality questions that sponsors should be thinking through before any final rule arrives. Meanwhile, FDA’s single IRB rule for cooperative research (RIN 0910-AI08) is listed at final rule stage with a December 2026 target, requiring U.S. institutions in multisite FDA-regulated studies to rely on one IRB for the domestic portion, plus adding recordkeeping requirements for institutions using an outside IRB. That one is closer to the finish line than the others.
On the human subjects side, OHRP is considering revisions to 45 CFR 46 (RIN 0937-AA16) that would add exemptions for low-risk research, create flexibility for de minimis protocol changes, and reduce burden for learning health systems. The direction is clearly toward concentrating oversight on higher-risk activity, but the NPRM is only targeted for July 2026, meaning the comment period and agency review still lie ahead. Practical implication: organizations can map their current low-risk protocols against the proposed exemption categories without committing to any process changes yet.
The Advarra team frames the agenda around five organizing shifts, including technology-enabled oversight and greater reliance on documented organizational judgment, categories DHHS itself does not use but that help operations teams route the right actions to the right internal owners. The single most useful near-term move is distinguishing the December 2026 final-rule targets from the mid-2026 NPRM targets: the cooperative research single-IRB rule is the one item where preparation, not just monitoring, is justified today.
Source link: https://www.advarra.com/blog/2026-dhhs-unified-agenda-what-clinical-research-leaders-need-to-know/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
